Topic: Amphinex with Gemcitabine phase 1 trial ends.

"Lysaker, 11 April 2014 - PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the treatment evaluation of the first dose cohort in the phase I/II study of Amphinex in combination with the cytotoxic agent gemcitabine in patients with inoperable bile duct cancer (cholangiocarcinoma) is completed. No safety concerns were observed at this dose level." … 1082031361

Any advice or comments I give are based on personal experiences and knowledge and are my opinions only, they are not to be substituted for professional medical advice. Please seek professional advice from a qualified doctor or medical professional.